| Intradepartmental Council for Native American Affairs (ICNAA) |
Committee, Work group, Advisory group, or Task Force |
OS |
NIMHD |
To support activities of the ICNAA, including tribal consultation sessions, and development of the annual tribal consultation report. |
| Joint Committee and Joint Commission Meetings |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA, OS |
NCI, FIC, NIAID |
US State Department establishes collaborative agreements with foreign governments in fields of science and technology. These Joint Committee and Joint Commission Meetings (JCMs) facilitate discussion on selected topics creating cross-talk among the equivalent government agencies leading towards future collaborations. The OS through OGA organizes the DHHS OP/DIVs; FIC facilitates the NIH ICs participation. For FY2011, JCMs were convened for Brazil, Colombia, and Mexico. |
| Kidney Interagency Coordinating Committee (KICC) |
Committee, Work group, Advisory group, or Task Force |
AHRQ, CDC, CMS, FDA, HRSA, IHS |
NIDDK, NHLBI |
The KICC Consists of Federal Representatives involved in chronic kidney disease (CKD) programs. KICC''s purpose is to encourage communication and collaboration to shape a more coordinated Federal response to CKD. |
| Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC) |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS |
NIAID, CSR, NCI, NCATS, NHLBI, NIA, NIAMS, NIDDK, NINR |
The Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC) was created in 1987, and continues to meet as subcommittees for kidney, urology, and hematology about four times a year. The committee is chaired by the Director, Division of Kidney, Urologic, and Hematologic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases and encourages cooperation, communication, and collaboration among all Federal agencies involved in kidney, urology, and hematology research and other activities. The members share information and advice about ongoing, new, and planned activities and identify potential areas of collaboration. |
| Lesbians, Gay, Bisexuals, and Transgender (LGBT) Coordinating Committee |
Committee, Work group, Advisory group, or Task Force |
ACF, AoA, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA |
NICHD, OD |
This committee includes senior representatives from each operating division to ensure coordination of and inclusion for LGBT populations throughout the Department''s activities. |
| Lupus Federal Working Group |
Committee, Work group, Advisory group, or Task Force |
AHRQ, CDC, FDA, HRSA, OS |
NIAMS, NCCAM, NEI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIMHD, NINDS, OD |
The Lupus Federal Working Group, established on behalf of the HHS Secretary by the NIH, facilitates collaboration among NIH components, other Federal agencies, voluntary and professional organizations, and industry groups with an interest in lupus. |
| Lyme Disease Coordinating Committee |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA |
NIAID, FIC, NCATS, NIA, NIAMS, NIMH, NINDS |
This committee reviews the results of current studies and recent advances in Lyme disease research. |
| Meta-Analysis of the Risk of Guillain-Barre Syndrome Following H1N1 Vaccination |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIAID |
Statistical expertise is offered in the design and analysis of multiple safety studies to assess the risk of Guillain-Barre Syndrome following H1N1 vaccination |
| Microbicide Trials Network Executive Committee |
Committee, Work group, Advisory group, or Task Force |
FDA |
OD/DPCPSI/OAR, NIAID, NICHD, NIMH, OD |
A committee designed to make strategic decisions and prioritize research for the MTN |
| Microsystems Team |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIDDK, NINDS, OD |
The NIH has identified a critical need for improved model systems to predict efficacy, safety, bioavailability, and toxicology outcomes for candidate therapeutics. This NIH FOA, supported by funds from the NIH Common Fund and participating NIH IC''s, invites applications for projects that will develop accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity. By definition, these cellular and organ microsystems will have a multicellular architecture representing the characteristics and functions of the tissue of origin and will demonstrate a reproducible and viable operation under physiological conditions over a long culture period. It is anticipated that these bio-engineered human tissue models could lead to the development and commercialization of microsystems that will enable rapid and high fidelity evaluation of safety and efficacy for candidate therapeutics. |